Breckenridge, Aggrega Pharma sign multiproduct agreement

Breckenridge has signed a multiproduct agreement with Aggrega Pharma under which the latter will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.

The agreement currently covers eight products in a variety of dosage forms, including solid oral, nasal spray, ophthalmic, injectable and transdermal. For these eight products, one ANDA has been approved, four ANDAs have been submitted to the Food and Drug Administration and three ANDAs are at advanced stages of development.

Breckenridge previously launched succinylcholine chloride injection 20 mg/mL under this agreement, which is now available as a carton of 25 vials. 

According to industry sales data, these eight products and their generics had annual sales of $500 million during the 12 months ending April 2021.